Fresenius Medical Care AG & Co. KGaA Sponsored ADR Aktie News

High-Volume Hemodiafiltration is used for the first time in seven out of 10 CCINSHAE centers in Mexico In Mexico, 240 CCINSHAE patients are now being treated; more than 410 regular patients also treated Fresenius Medical Care is committed to expanding HighVolumeHDF therapy to all markets where it is not already present, including the United States BAD HOMBURG, Germany , July 3, 2025 /PRNewswire...

EXCLUSIVE: The dialysis company believes the impact of the treatments on its own performance will be ‘neutral to positive' rather than negative.

FME Reignite sets the ambition to lead kidney care through exceptional patient care and innovation The Company will set the new standard of care in the U.S. with the introduction of the 5008X dialysis machine and unveils launch plans Profitability aspirations set for 2030 to advance to mid-teens percent industry-leading operating income1 margins FME25+ savings target expanded by EUR 300 million...

The world's largest dialysis specialist Fresenius Medical Care said, ahead of its capital markets day on Tuesday, that it plans to embark on a 1 billion euros ($1.16 billion) share buyback programme.

Updated 5008X CAREsystem with Additional Features Receives FDA 510(k) Clearance Company announces first wave of Fresenius Kidney Care clinics in the U.S. to begin offering  high-volume hemodiafiltration therapy to dialysis patients Introducing the 5008X CAREsystem and hemodiafiltration kidney replacement therapy is a key pillar of the company's growth strategy BAD HOMBURG, Germany , June 4, 202...

Key abstract presentations showcase significant advancements in clinical care, artificial intelligence, and fluid management, demonstrating Fresenius Medical Care's commitment to improving patient outcomes. Top Abstract recognition for "Prevalence and Patterns of Intradialytic Arterial Oxygen Saturation Instability: Observations in a Large U.S. Hemodialysis Cohort," presented in the "Dialysis" ...

Shareholders approved the proposed dividend of 1.44 Euro per share, representing a 21 percent increase year-over-year and marking the highest dividend in the company's history Excellent progress in the company's transformation and turnaround plans continues to strengthen the foundation for sustainable, profitable growth In 2024, organic revenue growth1 was 4 percent, and operating income increa...

Strong organic revenue growth1 of 5% driven by Care Enablement and Care Delivery Stable U.S. same market treatment development despite impact from a severe flu season FME25 savings of EUR 68 million contributed to earnings Operating income2 grew 11% at constant currency resulting in margin expansion Reported operating income grew by 35% and reported net income3 by 113% Net leverage ratio furthe...